CTSA

CTSA (protective protein/cathepsin A, PPCA) is a lysosomal serine carboxypeptidase that serves dual roles as a catalytic enzyme and as an essential stabilizer of β-galactosidase and neuraminidase within a multienzyme complex. Active-site mutagenesis demonstrates that its carboxypeptidase activity and its protective/stabilizing function are mechanistically separable: catalytic-dead mutants still rescue β-galactosidase and neuraminidase activities in galactosialidosis cells, whereas folding-defective mutants abolish both functions (PMID:1907282, PMID:3136930). PPCA cleaves LAMP2a at the lysosomal membrane, thereby controlling chaperone-mediated autophagy rates; cells lacking PPCA accumulate LAMP2a and exhibit elevated CMA, a phenotype reversed by restoring protease activity (PMID:12505983). Loss-of-function mutations in CTSA cause galactosialidosis, a lysosomal storage disorder characterized by combined deficiency of neuraminidase and β-galactosidase (PMID:40165614, PMID:3922758).

1. 1985 High

   Establishing that neuraminidase and β-galactosidase require a third protein for activity answered the fundamental question of why both enzymes are simultaneously deficient in galactosialidosis.

   Evidence Affinity chromatography, immunotitration, and density gradient sedimentation in human fibroblast lysates

   PMID:3922758

   Open questions at the time

   • Identity and sequence of the protective protein were unknown
   • Whether the protective protein had intrinsic enzymatic activity was untested
2. 1988 High

   Cloning of the PPCA cDNA revealed a 452-residue precursor with homology to serine carboxypeptidases, providing the molecular identity of the protective protein and predicting catalytic function.

   Evidence cDNA cloning and functional rescue of β-galactosidase/neuraminidase in galactosialidosis fibroblasts

   PMID:3136930

   Open questions at the time

   • Whether the predicted carboxypeptidase activity was real and whether it was separable from the protective function
   • Endogenous substrates of the carboxypeptidase were unknown
3. 1990 High

   Identification of platelet-derived deamidase/carboxypeptidase as PPCA established that the enzyme acts on bioactive peptides (substance P, bradykinin) outside the lysosome, broadening its functional repertoire beyond lysosomal housekeeping.

   Evidence Purification to homogeneity from human platelets, N-terminal sequencing matching PPCA, DFP active-site labeling

   PMID:1694176

   Open questions at the time

   • Physiological significance of extracellular peptide metabolism in vivo was not demonstrated
   • Mechanism of PPCA sorting to platelet secretory granules was unknown
4. 1991 High

   Active-site mutagenesis separated catalytic activity from protective function, proving PPCA uses distinct mechanisms for enzyme stabilization versus substrate hydrolysis — a key conceptual advance for understanding galactosialidosis pathogenesis.

   Evidence Ser/His active-site and Cys60 mutants expressed in COS-1 cells with quantitation of cathepsin A activity and β-galactosidase/neuraminidase stabilization

   PMID:1907282

   Open questions at the time

   • Structural basis of the protective interaction with β-galactosidase/neuraminidase was not resolved
   • Whether protective function requires specific PPCA domains beyond Cys60-dependent folding was unexplored
5. 2003 High

   Discovery that PPCA cleaves LAMP2a to control chaperone-mediated autophagy revealed a previously unknown lysosomal quality-control circuit and provided the first identified endogenous protein substrate for cathepsin A's carboxypeptidase activity in the lysosome.

   Evidence PPCA-deficient cells show elevated LAMP2a and CMA; restoration of protease activity reverses phenotype; co-association and cleavage site mapping

   PMID:12505983

   Open questions at the time

   • Exact cleavage site residues on LAMP2a were mapped but structural context of the protease–substrate interaction is lacking
   • Whether PPCA regulates CMA in vivo under physiological stress was not tested
6. 2018 Medium

   Identification of miR-106b-5p as a direct post-transcriptional repressor of CTSA via its 3′ UTR established a regulatory layer controlling CTSA abundance with functional consequences for cancer cell metastasis.

   Evidence Luciferase 3′ UTR reporter, rescue experiments, in vivo tail-vein metastasis model in colorectal cancer

   PMID:30013364

   Open questions at the time

   • Relevance to endogenous miR-106b-5p levels in non-cancer physiology was not addressed
   • Whether CTSA's pro-metastatic effect operates through LAMP2a/CMA or another substrate was not dissected
7. 2020 Medium

   Leptin-mediated suppression of CTSA expression in mammary carcinoma cells linked extracellular metabolic signaling to LAMP2a stability and CMA activation, contextualizing CTSA's role in obesity-associated tumor biology.

   Evidence RT-PCR, Western blot, immunocytochemistry, lysosome isolation in canine mammary carcinoma cells treated with leptin

   PMID:33255835

   Open questions at the time

   • Findings are from a single canine cell line; human relevance is unconfirmed
   • Mechanism by which leptin transcriptionally or post-transcriptionally downregulates CTSA was not defined
8. 2025 Medium

   A novel CTSA p.Gln436Arg variant causing galactosialidosis was shown to impair PPCA dimerization, linking specific residue-level defects to loss of both enzymatic and protective functions through disrupted protein maturation.

   Evidence Exome/Sanger sequencing in Thai patients, in vitro dimerization and enzyme activity assays

   PMID:40165614

   Open questions at the time

   • Structural modeling of how Gln436Arg disrupts dimerization interface is lacking
   • Whether partial dimerization rescue could restore protective function independently of catalytic activity was not tested

• The structural basis of the PPCA–β-galactosidase–neuraminidase ternary complex, the full repertoire of endogenous PPCA substrates, and the in vivo physiological consequences of PPCA-regulated CMA remain unresolved.
• No high-resolution structure of the ternary complex exists
• Comprehensive substrate profiling (e.g., degradomics) for cathepsin A has not been performed
• In vivo genetic models testing CMA-dependent phenotypes of CTSA loss are limited